Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials
DOI10.1080/03610929808832163zbMATH Open0915.62089OpenAlexW2062627724MaRDI QIDQ3842893FDOQ3842893
Authors: T. Timothy Chen, Edward L. Korn, Stewart J. Anderson, Anne S. Lindblad, Harold O. Jun. Douglass, Bernard Fisher, J. Michael Hamilton, Michael Friedman, Richard Simon, Harry S. Wieand 
Publication date: 30 June 1999
Published in: Communications in Statistics: Theory and Methods (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1080/03610929808832163
Recommendations
- Exploring and validating surrogate endpoints in colorectal cancer
- Statistical evaluation of surrogate endpoints with examples from cancer clinical trials
- Analyzing survival data in conjunction with time-dependent surrogate endpoints in clinical trials
- Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
- Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials
Cites Work
- Inference using surrogate outcome data and a validation sample
- A Stochastic Model for Censored-Survival Data in the Presence of an Auxiliary Variable
- A Two-Stage Procedure for Survival Studies with Surrogate Endpoints
- Analyzing survival data in conjunction with time-dependent surrogate endpoints in clinical trials
- Using surrogate failure time data to increase cost effectiveness in clinical trials
Cited In (2)
This page was built for publication: Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3842893)
